Cargando…
The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
BACKGROUND: In chronic diseases such as multiple sclerosis requiring lifelong treatment, studies on long-term outcomes are important. OBJECTIVE: To assess disability and magnetic resonance imaging-related outcomes in relapsing multiple sclerosis patients from a Phase 2 study of fingolimod 10 or more...
Autores principales: | Derfuss, T, Sastre-Garriga, J, Montalban, X, Rodegher, M, Wuerfel, J, Gaetano, L, Tomic, D, Azmon, A, Wolf, C, Kappos, L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132565/ https://www.ncbi.nlm.nih.gov/pubmed/32284874 http://dx.doi.org/10.1177/2055217320907951 |
Ejemplares similares
-
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020) -
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing‐remitting multiple sclerosis
por: Langdon, Dawn W., et al.
Publicado: (2021) -
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
por: Kuhle, Jens, et al.
Publicado: (2015) -
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016) -
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)